Q2 2026 13F · SEC CIK 1388325

Novo Holdings A/s

Investment managerFiled 2026-08-14 for Q2 2026. Open the filing ↗ · All SEC filings ↗

Reported 13F value: $1.7B
Reported positions: 25
Top holdings a year, 3 yrs: +26.4%
Average holding period: 2.6 yrs

Novo Holdings A/s is an investment manager that reported 25 positions worth $1.7B in its Q2 2026 13F, filed 2026-08-14. Its largest holdings were Edgewise Therapeutics Inc (EWTX, 12.6%), Asml Hldg NV (ASML, 11.0%), Hemab Therapeutics Holdings Inc (COAG, 8.9%). A portfolio copying its top holdings returned 26.4% a year over the last 3 years, against 20.4% for the S&P 500.

Novo Holdings A/s holdings all 25 positions.

Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.

Novo Holdings A/s 13F holdings
Stock	% of 13F value	Q1 2026	Shares	Share change	Reported value
EWTXEdgewise Therapeutics Inc	12.6%	13.7%	5,350,000	+0.0%	$217.4M
ASMLAsml Hldg NV	11.0%	10.2%	94,946	+0.0%	$188.9M
COAGHemab Therapeutics Holdings Inc	8.9%	New	4,180,550	—	$153.6M
BNBrookfield Corp	8.7%	11.5%	3,496,245	+0.0%	$149.5M
MPLTMaplight Therapeutics Inc	7.7%	6.1%	3,686,622	+0.0%	$132.1M
MIRMMirum Pharmaceuticals Inc	7.6%	9.9%	1,125,000	-15.1%	$131.7M
AVLNAvalyn Pharmaceuticals Inc	7.4%	New	3,883,289	—	$127.8M
CRMSalesforce Inc	3.6%	5.9%	393,187	+0.0%	$61.6M
AVBPArrivent Biopharma Inc	3.0%	3.6%	1,500,000	-22.8%	$52.1M
ELVNEnliven Therapeutics Inc	2.9%	4.1%	1,000,000	-21.9%	$50.8M
CRNXCrinetics Pharmaceuticals in	2.9%	4.6%	1,320,000	-14.8%	$49.4M
PHVSPharvaris N V	2.8%	4.0%	1,400,000	-20.0%	$48.4M
FNDFloor & Decor Hldgs Inc	2.7%	New	797,000	—	$47.3M
PCVXVaxcyte Inc	2.7%	4.0%	800,000	-7.0%	$46.5M
FDMT4d Molecular Therapeutics in	2.5%	2.8%	3,249,178	-11.0%	$43.2M
VRDNViridian Therapeutics Inc	2.3%	3.2%	2,135,000	+6.7%	$39.2M
CLDXCelldex Therapeutics Inc New	2.2%	3.1%	1,025,000	-14.6%	$38.1M
ALMSAlumis Ord	1.8%	New	1,100,000	—	$31.0M
XENEXenon Pharmaceuticals Inc	1.7%	2.3%	485,438	+0.0%	$29.3M
BABAAlibaba Group Hldg Ltd	1.4%	2.6%	257,327	+0.0%	$24.7M
DYNDyne Therapeutics Inc	1.2%	New	960,394	—	$21.3M
BBOTBridgebio Oncology Therapeut	1.0%	1.6%	2,250,000	+2.9%	$17.1M
INSMInsmed Inc	0.7%	New	120,723	—	$12.9M
MQMarqeta, Inc.	0.4%	0.1%	441,558	+0.0%	$7.2M
LNZALanzatech Global Inc	0.1%	0.2%	158,148	+0.0%	$1.1M

What Novo Holdings A/s bought and sold in Q2 2026, against Q1 2026.

Share counts compared with the Q1 2026 13F; a split also changes share counts.

How the holdings did against the S&P 500.

1 year: +54.0% /yr; S&P 500 +20.1%
3 years: +26.4% /yr; S&P 500 +20.4%
5 years: +11.1% /yr; S&P 500 +11.6%

A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.

Reported 13F value by quarter.

13F value by quarter
Quarter	13F value	Positions
Q2 2026	$1.7B	25
Q1 2026	$1.2B	22
Q4 2025	$1.3B	24
Q3 2025	$1.6B	27
Q2 2025	$1.4B	29
Q1 2025	$1.3B	31
Q4 2024	$1.7B	34
Q3 2024	$2.0B	37
Q2 2024	$1.9B	38
Q1 2024	$1.4B	35
Q4 2023	$1.6B	36
Q3 2023	$1.4B	40

Questions about Novo Holdings A/s's portfolio

What stocks does Novo Holdings A/s own?

Novo Holdings A/s's latest 13F, for Q2 2026 and filed Aug 14, 2026, lists 25 positions worth $1.7B. The largest are Edgewise Therapeutics Inc (EWTX) at 12.6%, Asml Hldg NV (ASML) at 11.0%, Hemab Therapeutics Holdings Inc (COAG) at 8.9%, Brookfield Corp (BN) at 8.7% and Maplight Therapeutics Inc (MPLT) at 7.7%.

What did Novo Holdings A/s buy last quarter?

In Q2 2026, Novo Holdings A/s added a new position in Hemab Therapeutics Holdings Inc (COAG), a new position in Avalyn Pharmaceuticals Inc (AVLN), a new position in Floor & Decor Hldgs Inc (FND), a new position in Alumis Ord (ALMS), a new position in Dyne Therapeutics Inc (DYN) and Viridian Therapeutics Inc (VRDN) (+6.7% shares), compared with its Q1 2026 filing.

What did Novo Holdings A/s sell last quarter?

In Q2 2026, Novo Holdings A/s sold all of Apogee Therapeutics Inc (APGE), sold all of Biomarin Pharmaceutical Inc (BMRN), sold all of Valneva SE (VALN), Arrivent Biopharma Inc (AVBP) (-22.8% shares), Enliven Therapeutics Inc (ELVN) (-21.9% shares) and Pharvaris N V (PHVS) (-20.0% shares), compared with its Q1 2026 filing.

How has Novo Holdings A/s's portfolio performed?

A portfolio copying Novo Holdings A/s's 20 largest 13F holdings each quarter, from the day each filing was public, returned +26.4% a year over the last 3 years, against +20.4% for the S&P 500. Over 1 year: +54.0% against +20.1%. Over 5 years: +11.1% a year against +11.6%.

When is Novo Holdings A/s's next 13F filing due?

13F filings are due 45 days after each quarter ends. Novo Holdings A/s's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.